Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in vivo against B:15:P1.7,16 subtype variants in an infant rat infection model

Microbial Pathogenesis

Volumn 30, Issue 3, 2001, Pages 139-148

  Toropainen, Maija ^a,b   Saarinen, Leena ^a,b   Van Der Ley, Peter ^a,b   Kuipers, Betsy ^a,b   Käyhty, Helena ^a,b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Bactericidal activity; Infant rat infection model; Monoclonal antibodies; Neisseria meningitidis; PorA; Whole cell EIA

Indexed keywords

BACTERIAL PROTEIN; EPITOPE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PORA PROTEIN ANTIBODY; PORIN A; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; BLOOD CULTURE; ENZYME IMMUNOASSAY; IMMUNIZATION; IN VIVO STUDY; INFECTION; NEISSERIA MENINGITIDIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; RAT;

ANIMALIA; MURINAE; NEISSERIA MENINGITIDIS;

EID: 0034978482     PISSN: 08824010     EISSN: None     Source Type: Journal    
DOI: 10.1006/mpat.2000.0419     Document Type: Article

References (42)

1. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba
2. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway
3. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil
4. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile
5. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine
6. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting
7. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine
8. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: A brief survey
9. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile
10. Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA
11. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes
12. Specificity of bactericidal antibody response to sero-group B meningococcal strains in brazilian children after immunization with an outer membrane vaccine
13. The class 1 outer membrane protein of Neisseria meningitidis: Gene sequence and structural and immunological similarities to gonococcal porins
14. Deduced amino acid sequences of class 1 protein (PorA) from three strains of Neisseria meningitidis. Synthetic peptides define the epitopes responsible for serosubtype specificity
15. Comparison of the class 1 outer membrane proteins of eight serological reference strains of Neisseria meningitidis
16. Topology of outer membrane porins in pathogenic Neisseria spp
17. Structural and evolutionary interference from molecular variation in Neisseria porins
18. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978
19. Sequencing of porA from clinical isolates of Neisseria meningitidis defines a subtyping scheme and its genetic regulation
20. Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design
21. The porA gene in serogroup A meningococci: Evolutionary stability and mechanism of genetic variation
22. Class 1 outer membrane protein of Neisseria meningitidis: Epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology
23. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: New prospects for vaccine development
24. Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins
25. Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: Implications for serological typing and vaccine design
26. A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine
27. Point mutation in meningococcal por A gene associated with increased endemic disease
28. Meningococcal outbreak in Southern Finland
29. The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci
30. Role of horizontal genetic exchange in the antigenic variation of the class 1 outer membrane protein of Neisseria meningitidis
31. Population genetics of a transformable bacterium: The influence of horizontal genetic exchange on the biology of Neisseria meningitidis
32. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine
33. On the interaction between a bactericidal antibody and a PorA epitope of Neisseria meningitidis in outer membrane vesicles: A competitive fluorescence polarization immunoassay
34. Thermodynamic analysis of the interaction between a bactericidal antibody and a PorA epitope of Neisseria meningitidis
35. Bactericidal antibody recognition of a PorA epitope of Neisseria meningitidis: Crystal structure of a Fab fragment in complex with a fluorescein-conjugated peptide
36. The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis
37. Experimental meningococcal meningitis in the infant rat
38. Development, characterization, and biological properties of meningococcal immunotype L3,7,(8),9-specific monoclonal antibodies
39. Preparation and application of a fluoresceinlabeled peptide for determining the affinity constant of a monoclonal antibody-hapten complex by fluorescence polarization
40. NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: Isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci
41. Whole-cell ELISA for typing Neisseria meningitidis with monoclonal antibodies
42. Variation in the expression of pili and outer membrane protein by Neisseria meningitidis during the course of meningococcal infection